The hematopoietic stem cell concentrations in tissues of homozygous beta-thalassemic and non-thalassemic fetuses and neonates were compared by using the spleen colony-forming units (CFU-S) assay. The relative quantities of embryonic and adult hemoglobins were also determined for fetuses. Beta-thalassemic fetuses had a reduced incidence of CFU-S in the liver throughout gestation, but after birth the beta-thalassemic neonates maintained a greater number of CFU-S in the liver for an extended period. The incidence of CFU-S in the bone marrow was not different for the two groups. The beta-thalassemic mice exhibited a significant expansion of CFU-S in the spleen beyond 11 days after birth. The switch from the synthesis of primarily embryonic to primarily adult hemoglobins in circulating erythrocytes in beta-thalassemic fetuses appeared later than the switch in normal fetuses. These observations establish that the developmental timing and expansion of hematopoiesis are perturbed in beta-thalassemic mice.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Accumulation of free α-globin is a critical factor in the pathogenesis of β-thalassemia. Autophagy plays a crucial role in clearing toxic free α-globin, thereby reducing disease severity. However, the impact of natural mutations in autophagy-related genes (ATGs) on the phenotypic variability of β-thalassemia remains unclear.
View Article and Find Full Text PDFA novel synthetic compound, deferiprone-resveratrol hybrid (DFP-RVT), promotes hepatoprotective effects and ameliorates iron-induced oxidative stress in iron-overloaded β-thalassemic mice.
Biomed Pharmacother
November 2024
Department of Biochemistry, Faculty of Medicine, Chiang Mai University, Chiang Mai 50200, Thailand. Electronic address:
A high amount of iron in β-thalassemia patients can lead to oxidative stress and organ dysfunction, especially liver, the main iron accumulated organ. Iron catabolism causes the generation of reactive oxygen species (ROS), triggering liver inflammation, fibrosis, and cirrhosis. Deferiprone-resveratrol hybrid (DFP-RVT) is chemically synthesized by combining deferiprone (DFP) and resveratrol (RVT) which shows an iron-chelating property along with antioxidant activity.
View Article and Find Full Text PDFExpression of microRNA-155 in thalassemic erythropoiesis.
PeerJ
September 2024
Faculty of Medical Technology, Prince of Songkla University, Hat Yai, Songkhla, Thailand.
Article Synopsis
- Ineffective erythropoiesis (IE) leads to anemia in beta-thalassemia, characterized by increased erythroblast proliferation without proper differentiation, resulting in immature red blood cells (RBCs).
- The study investigates the role of microRNA-155 (miR-155) in beta-thalassemia, focusing on its expression in erythroid cells from thalassemic bone marrow and its effects on cell differentiation and proliferation.
- Results show that miR-155 is upregulated during erythropoiesis in thalassemic mice, and manipulating its expression alters erythroid cell proliferation and differentiation, suggesting its potential significance in managing thalassemia-related anemia.
Non-viral DNA delivery and TALEN editing correct the sickle cell mutation in hematopoietic stem cells.
Nat Commun
June 2024
Cellectis S.A., 8 Rue de la Croix Jarry, Paris, France.
Sickle cell disease is a devastating blood disorder that originates from a single point mutation in the HBB gene coding for hemoglobin. Here, we develop a GMP-compatible TALEN-mediated gene editing process enabling efficient HBB correction via a DNA repair template while minimizing risks associated with HBB inactivation. Comparing viral versus non-viral DNA repair template delivery in hematopoietic stem and progenitor cells in vitro, both strategies achieve comparable HBB correction and result in over 50% expression of normal adult hemoglobin in red blood cells without inducing β-thalassemic phenotype.
View Article and Find Full Text PDFBone marrow Tfr2 deletion improves the therapeutic efficacy of the activin-receptor ligand trap RAP-536 in β-thalassemic mice.
Am J Hematol
July 2024
Regulation of Iron Metabolism Unit, Division of Genetics and Cell Biology, IRCCS Ospedale San Raffaele, Milan, Italy.
β-thalassemia is a disorder characterized by anemia, ineffective erythropoiesis (IE), and iron overload, whose treatment still requires improvement. The activin receptor-ligand trap Luspatercept, a novel therapeutic option for β-thalassemia, stimulates erythroid differentiation inhibiting the transforming growth factor β pathway. However, its exact mechanism of action and the possible connection with erythropoietin (Epo), the erythropoiesis governing cytokine, remain to be clarified.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!